This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2007 by National Cancer Center, Korea.
Recruitment status was:  Recruiting
Information provided by:
National Cancer Center, Korea Identifier:
First received: July 23, 2007
Last updated: NA
Last verified: July 2007
History: No changes posted
From 100 colorectal cancer patients being treated with FOLFIRI regimen or any kind of irinotecan containing regimen, blood samples for irinotecan and its metabolites levels and genotypes related with its metabolism will be collected. The association of their levels and genotypes and treatment effects will be evaluated.

Condition Intervention
Colorectal Neoplasms Secondary Drug: irinotecan

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Clinical Study for the Evaluation of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on the Pharmacokinetics and Treatment Effects of Irinotecan in Patients With Colorectal and Gastric Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Center, Korea:

Primary Outcome Measures:
  • SLCO1B1 and PXR genotypes and maximal response rate [ Time Frame: Before & during treatment ]
  • SLCO1B1 and PXR genotypes and pharmacokinetics of SN-38 [ Time Frame: Before and 1st cycle ]

Secondary Outcome Measures:
  • SLCO1B1 and PXR genotypes and response duration, time to progression and overall survival

Estimated Enrollment: 100
Study Start Date: August 2006
Estimated Study Completion Date: December 2008
Detailed Description:

For the genotype-PD association, 50 colorectal cancer patients treated with FOLFIRI will be enrolled and studied. 50 additional colorectal patients treated with any kind of irinotecan containing regimen will be enrolled and including the 50 patients for the genotype-PD association, a total of 100 patients will be evaluated for the genotype-PK association.

Blood samples for PK analysis will be collected from patients with colorectal cancer during 1st treatment cycle of irinotecan and 2nd, 3rd infusion. During the 1st treatment cycle, blood will be drawn 0 h (before irinotecan infusion), 0.75 h, 1.5 h and each at time ranges of 2~8 h, 8~16 h, 24~32h and 48~52 hours after the start of irinotecan infusion over 90 min and additional blood will be collected 48~52 hours after the respective 2nd and 3rd infusion.

For 50 colorectal cancer patient treated with FOLFIRI regimen, responses to the treatment will be assessed every 3 cycles. All assessments will be repeated at the end of trial therapy.

The RECIST criteria for measurable disease will be followed and toxicity will be evaluated according to NCI common toxicity criteria version 3.0.

Time to disease progression will be calculated from the date of study entry to the first objective documentation of progressive disease. Response duration will be measured from the date a patient first fulfills the CR or PR criteria to the first date of objective documentation of disease progression.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically diagnosed unresectable or metastatic colorectal cancer
  • Performance status of 0, 1 and 2 on the ECOG criteria
  • Disease status must be that of measurable disease as defined by RECIST criteria (For genotype-PD study only) Only non-target lesions are allowed for PK study
  • No previous chemotherapy, radiotherapy on the target lesion, immunotherapy; adjuvant chemotherapy with fluoropyrimidines completed at least 6 months ago is allowed (For genotype-PD study only) Previously treated patients are allowed for PK study
  • Life expectancy of more than 3 months (For genotype-PD study only)
  • Adequate major organ functions
  • Compliant patient who can be followed-up adequately
  • Informed consent

Exclusion Criteria:

  • Active or uncontrolled infection
  • Pregnant or breast-feeding women
  • Patients with systemic disease, especially cardiovascular disease, who cannot tolerate systemic chemotherapy
  • Patients with brain metastasis (For genotype-PD study only)
  • Patients treated with radiotherapy within 2 weeks (For genotype-PD study only)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00507143

Contact: Kyung Hae Jung, M.D. +82-31-920-1611
Contact: Eun Kyung Shim +82-31-920-1145

Korea, Republic of
National Cancer Center Korea Recruiting
Goyang, Gyeonggi, Korea, Republic of, 410-769
Sub-Investigator: Yong Sang Hong, M.D.         
Sub-Investigator: Hyeong-Seok Lim, M.D.         
Sub-Investigator: Sun Young Kim, M.D.         
Sub-Investigator: Hye Suk Han, M.D.         
Sub-Investigator: Sun Lim         
Sponsors and Collaborators
National Cancer Center, Korea
Principal Investigator: Kyung Hae Jung, M.D.
  More Information Identifier: NCT00507143     History of Changes
Other Study ID Numbers: NCCCTS-06-206
Study First Received: July 23, 2007
Last Updated: July 23, 2007

Keywords provided by National Cancer Center, Korea:
Colorectal neoplasms

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 23, 2017